Beyond DNA repair: additional functions of PARP-1 in cancer

Alice N. Weaver¹ and Eddy S. Yang¹,²,³ *

¹ Department of Radiation Oncology, School of Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA
² Department of Cell, Developmental, and Integrative Biology, School of Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA
³ Department of Pharmacology and Toxicology, School of Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA

Poly(ADP-ribose) polymerases (PARPs) are DNA-dependent nuclear enzymes that transfer negatively charged ADP-ribose moieties from cellular nicotinamide-adenine-dinucleotide (NAD⁺) to a variety of protein substrates, altering protein–protein and protein–DNA interactions. The most studied of these enzymes is poly(ADP-ribose) polymerase-1 (PARP-1), which is an excellent therapeutic target in cancer due to its pivotal role in the DNA damage response. Clinical studies have shown susceptibility to PARP inhibitors in DNA repair defective cancers with only mild adverse side effects. Interestingly, additional studies are emerging which demonstrate a role for this therapy in DNA repair proficient tumors through a variety of mechanisms. In this review, we will discuss additional functions of PARP-1 – including regulation of inflammatory mediators, cellular energetics and death pathways, gene transcription, sex hormone- and ERK-mediated signaling, and mitosis – and the role these PARP-1-mediated processes play in oncogenesis, cancer progression, and the development of therapeutic resistance. As PARP-1 can act in both a pro- and anti-tumor manner depending on the context, it is important to consider the global effects of this protein in determining when, and how, to best use PARP inhibitors in anticancer therapy.

Keywords: PARP-1, PARP inhibitors, NF-κB, genetic transcription, sex hormone signaling, ERK signaling, angiogenesis, mitotic spindle

INTRODUCTION

Poly(ADP-ribose) polymerase-1 (PARP-1) is a nuclear enzyme which binds DNA via two zinc finger motifs and transfers chains of ADP-ribose moieties from cellular nicotinamide-adenine-dinucleotide (NAD⁺) to chromatin-associated acceptor proteins, including PARP-1 itself. This post-translational modification plays an important role in promoting DNA repair by releasing PARP-1 from DNA and allowing for recruitment of proteins involved in both base excision repair (BER) and homologous recombination (HR) (1). Accordingly, PARP-1 is an attractive anticancer target, and poly(ADP-ribose) polymerase (PARP) inhibitors have been identified as chemo- and radiation-sensitizing agents in an array of cancers (2–5), including our report on the sensitization in both base excision repair and homologous recombination (6). Perhaps the most well-known tumoricidal effects of PARP inhibitors are in BRCA-mutated cancers, which harbor DNA repair defects and become dependent on PARP-1-mediated repair for survival. Two landmark studies (7, 8) found inhibition of PARP-1 in cells containing BRCA mutations resulted in the generation of chromatid breaks, G2 cell cycle arrest, and enhancement of apoptosis, results which have been confirmed in early phase clinical trials (9, 10).

Interestingly, recent studies also show potential efficacy of PARP inhibition in sporadic tumors lacking DNA repair defects. A clinical study of the PARP inhibitor olaparib in women with heavily pretreated high-grade serous ovarian cancer without germline BRCA1/2 mutations resulted in objective responses in 11/46 (24%) (11), indicating there may be additional determinants of sensitivity to PARP inhibition. Pre-clinical studies have identified susceptibility to PARP inhibition alone in HR-proficient HER2-positive breast cancer, pancreatic cancer, prostate cancer, Ewing's sarcoma, small cell lung carcinoma, and neuroblastoma, among others (12–17). These reports demonstrate the existence of non-DNA repair functions of PARP-1 that may be targetable for cancer treatment. It is thus becoming increasingly apparent that a number of PARP-1-mediated cellular processes influence characteristics of tumor development, progression, and treatment response, including several of the eight “hallmarks of cancer” proposed by Hanahan and Weinberg (18) (Figure 1). In this review, we will discuss cancer-related functions of PARP-1 – including regulation of inflammatory mediators through NF-κB, cell death and energetics, ERK-mediated tumor progression and invasion, mitosis, gene transcription, and sex hormone signaling – and examples of how these functions may be exploited to expand the patient population potentially benefiting from treatment with PARP inhibitors.

NF-κB-MEDIATED TUMOR-PROMOTING INFLAMMATION

In multiple cancers, including breast, prostate, and head and neck among others, the NF-κB signaling pathway undergoes a loss of regulation resulting in constitutive activation (19). Briefly, NF-κB is a family of transcription factors including RelA/p65, RelB, c-Rel, p50, and p52, which exist as homo- and hetero-dimers. DNA-binding affinity and DNA sequence specificity is dependent on the composition of the dimer. Inhibitory proteins bind NF-κB dimers

Edited by: Christina Annunziata, National Cancer Institute, USA
Reviewed by: Xu-Dong Zhu, McMaster University, Canada
Wen-Ming Yang, National Chung Hsing University, Taiwan
*Correspondence: Eddy S. Yang, Department of Radiation Oncology, School of Medicine, The University of Alabama at Birmingham, 176F HSROC Suite 2232N, 1700 6th Avenue South Birmingham, AL 35249-6832, USA e-mail: eyang@uab.edu

www.frontiersin.org
November 2013 | Volume 3 | Article 290 | 1
Weaver and Yang Non-DNA repair functions of PARP-1

FIGURE 1 | Non-DNA repair functions of PARP-1 influence the "hallmarks of cancer" (18). This schematic depicts multiple PARP-1-mediated processes which either stimulate or inhibit six of the eight "hallmarks of cancer," as indicated by green and red boxes respectively. These hallmarks, proposed by Hanahan and Weinberg, are malignant characteristics that provide a framework for understanding the biology of cancer.

and sequester them in the cytosol in the absence of a stimulus; pathway activation causes proteosomal degradation of inhibitors, allowing the dimer to translocate to the nucleus and activate pro-inflammatory transcription programs. Although NF-κB signaling mediates the acute immune response responsible for targeting and eliminating cancerous cells, chronic inflammation mediated by this “hallmark” pathway can lead to the malignant phenotype (Figure 1), facilitating escape from immune surveillance, cancer survival, metastasis, and angiogenesis (20).

Activation of NF-κB can be regulated by PARP-1 via multiple mechanisms (Figure 2). First, PARP-1 directly interacts with histone acetyl-transferases p300 and CREB-binding protein (CBP) to synergistically co-activate NF-κB-dependent gene expression. In response to inflammatory stimuli, p300/CBP acetylates PARP-1 at specific lysine residues. This modification is necessary for PARP-1-p50 interaction, enhancement of p300-p50 interaction, and co-activation of NF-κB-mediated transcription programs (21, 22). Co-activation is negatively regulated by the activity of class I histone deacetylases (HDACs) (22) and SUMO1/3-mediated SUMOylation of the automodification domain of PARP-1 (23). Second, enzymatic activation of PARP-1 variably affects NF-κB, with outcomes dependent on the identity of the PAR acceptor protein. AutoPARylation of PARP-1 following detection of DNA strand breaks promotes the formation of a “signalosome” containing IKKγ (NEMO), the regulatory subunit of a NF-κB inhibitory complex, along with PIASγ, and ATM. Chains of PAR on activated PARP-1 provide the scaffold needed for SUMOylation of IKKγ by the PIASγ PAR binding motif, leading to activation of IKK and NF-κB (24). The effects of PARylation on NF-κB itself are less clear, with different sources reporting decreased, increased, or unaffected DNA-binding activity (25–27). Taken together, these studies demonstrate a strong role for PARP-1 in regulating NF-κB activity.

The interaction between PARP-1 and the NF-κB pathway promotes production of pro-inflammatory cytokines such as TNFα, IL-6, INFγ, E-selectin, and ICAM-1, as well as expression of nitric oxide synthase (28–30); PARP inhibition has been shown to attenuate upregulation of these factors in response to inflammatory stimuli (28, 29). Furthermore, PARP inhibition may also prevent inflammation-associated adverse side effects of traditional chemotherapeutics (31), supporting the use of PARP inhibitors in multidrug regimens. Loss of PARP-1 activity not only decreases pro-tumor inflammation, but also inhibits two related hallmarks of cancer through anti-inflammatory mechanisms: proliferative signaling (32) and metastasis (33, 34) (Figure 1).

Recently, we discovered an unexpected sensitivity to PARP inhibition in DNA repair proficient HER2-positive breast cancer cells through attenuation of NF-κB-mediated signaling (13). HER2 over-expressing cancers have activated NF-κB, which acts to block apoptosis and possibly mediate resistance to HER2-targeted drugs (35). In HER2-positive breast cancer cells, treatment with PARP inhibitor significantly reduced the expression of NF-κB activator...
IKKα and phosphorylated p65 while increasing inhibitory IκBα. These events resulted in decreased NF-κB transcriptional activity in HER2-positive, but not HER2-negative, breast cancer cells (13). Furthermore, overexpression of HER2 alone was sufficient to confer sensitivity to PARP inhibitor, suggesting synthetic lethality with PARP inhibition in tumors that are oncogene-addicted to HER2 signaling, as those that are oncogene-addicted to HER2 can be sensitized to PARP inhibition (13). These results are contradicted by a recent report showing PHLPP1-mediated downregulation of Akt activity and increased cell death following PARP inhibition (50), although these results are contradictory to a recent report showing PHLPP1-mediated downregulation of Akt activity and increased cell death following PARP inhibition (51).

Clinically, targeting the role of PARP-1 in cell death pathways appears to be complex. PARP-1 inhibition may reduce PAR-mediated inactivation of caspase-8, sensitizing cancer cells to tumor necrosis factor-related apoptosis-induced ligand (TRAIL) therapy (37). Additionally, inhibition of PARP-1 prevents cisplatin- and methotrexate-induced ATP depletion and nephrotoxicity (42, 43), as well as imatinib (Gleevec)-induced JNK activation and cardiotoxicity (52), without significantly affecting the anticancer activity of these agents. However, activation of the Akt survival pathway may counteract the cytotoxic effects of PARP inhibition and cause resistance to therapy (47), suggesting Akt pathway inhibition may enhance PARP inhibition in anti-tumor therapy. Despite these complexities, the influence of PARP-1 on metabolic co-factors and cell death signaling is significant, and further studies examining the role of PARP inhibition in manipulating these processes is warranted.

**CELLULAR ENERGETICS AND CELL DEATH**

Cancer cells are characterized by excessive proliferation, impaired cell death signaling, and deregulated metabolism (Figure 1). These features are often mediated by altered mitochondrial activity coupled with inactivation of apoptotic signaling through decreased expression of pro-apoptotic factors like p53 or overexpression of anti-apoptotic factors like Bcl-x. Integrity of regulatory pathways for cell death and metabolism is important for response to many cancer treatment modalities, as well as in cancer imaging and diagnostics. Cellular energetics and death signaling are heavily regulated by PARP-1, allowing activity of this protein to serve as a switch between cell fates and to affect both tumor proliferation and therapeutic response.

In response to damage stimuli, activated PARP-1 acts early in the apoptosis initiation pathway to stabilize p53 and facilitate its function (36). If damage is excessive, high levels of PAR synthesis by PARP-1 deplete its NAD+ substrate; additional interactions between PARP-1 and NMNAT-1, a NAD+ synthase, and SIRT1, a NAD+-dependent protein deacetylase, further contribute to PARP-1 as a controller of NAD+ availability and, thus, NAD+-dependent metabolic reactions. ATP-dependent NAD+ salvage saps cellular ATP stores, resulting in energy deprivation and, eventually, energy crisis-induced necrosis (Figure 3).

Hyperactivation of PARP-1 and accumulation of PAR can also cause translocation of PAR to the cytosol, where it interacts with the outer mitochondrial surface. Here it binds apoptosis inducing factor (AIF) and induces its release and translocation to the nucleus, ultimately resulting in large-scale DNA fragmentation and a novel PARP-1-dependent cell death mechanism known as “parthanatos” (38). To prevent these events, activated caspasases cleave PARP-1 into two fragments: an 89-kDa C-terminal fragment with low levels of catalytic activity and a 24-kDa N-terminal peptide which inhibits the catalytic activity of uncleaved nuclear PARP-1. Conservation of NAD+ and, thus, ATP allows the cell to undergo programed cell death (39–41). Accordingly, inhibition of PARP-1 preserves ATP levels, improves antioxidant status, and normalizes anti-apoptotic Bcl-x levels in the kidney following chemotherapy-induced injury (42, 43).

Poly(ADP-ribose) polymerase-1 also regulates the classical necrototic pathway mediated by the death promoting MAP kinase, c-Jun N-terminal kinase (JNK). This signaling network is activated in many cancers and has been implicated as a driver of both tumor development and treatment response (44, 45). PARP-1 downregulates MAP kinase phosphatase MKP-1 expression and inhibits the survival kinase Akt, both of which activate JNK (46, 47), suggesting potential benefit for PARP inhibition in tumors with elevated JNK activity. JNK1 mediates phosphorylation and sustained activation of PARP-1, creating a feed-forward regulatory loop (48). In conjunction, PARP-1-induced depletion of ATP stimulates AMP-activated protein kinase (AMPK) while inhibiting mTOR to promote autophagy, yet another cell death pathway important in cancer survival and treatment response (49). Pharmacologic inhibition of PARP-1 promotes Akt activity and mTOR signaling resulting in decreased cell death (50), although these results are contradicted by a recent report showing PHLP1-mediated downregulation of Akt activity and increased cell death following PARP inhibition (51).

www.frontiersin.org

November 2013 | Volume 3 | Article 290 | 3
Weaver and Yang Non-DNA repair functions of PARP-1

FIGURE 3 | Poly(ADP-ribose) polymerase-1 acts as a switch between cell fates. Hyperactivation of PARP-1 and PAR synthesis depletes NAD and, subsequently, ATP. Elevated PAR can promote necrosis, autophagy, or AIF-induced parthanatos. In addition, PARylation inactivates caspase-8, inhibiting apoptotic signaling. Alternatively, activated caspases can cleave PARP-1; the resulting cleavage product inhibits uncleaved PARP-1, conserving NAD/ATP, and promoting apoptosis. These cell death pathways play a role in both cancer survival and response to anticancer therapy.

ERK-MEDIATED ANGIogenesis AND METASTASIS

In addition to the JNK-mediated signaling described previously, a second family of MAP kinases known as extracellular signal-regulated kinases or ERKs is involved not only in cell death determination but also in tumor progression, angiogenesis, and metastasis. ERK activation is pivotal in cancer cell survival through upregulation of anti-apoptotic proteins and inhibition of caspase activity (53). Inhibition of this pathway by targeting ERK or MEK, which is immediately upstream of ERK in signaling, has been associated with suppression of ovarian tumor growth (54), reduced metastatic potential of melanoma cells (55), and increased sensitivity to cytotoxic agents (56). Recent studies indicate an important role for PARP-1 in promoting ERK signaling.

Poly(ADP-ribose) polymerase-1 is activated and autoPARylated by a direct interaction with phosphorylated ERK2 (pERK2), resulting in enhanced pERK2-catalyzed phosphorylation of target transcription factors and increased gene expression (57). Furthermore, PARP inhibition causes loss of ERK2 stimulation by decreasing the activity of critical pro-angiogenic factors including vascular endothelial growth factor (VEGF), transmembrane signaling protein syndecan-4 (SDC-4), platelet/endothelial cell adhesion molecule (PECAM1/CD31), and hypoxia inducible factor (HIF). This ultimately results in reduced angiogenesis and inflammation (58–62). The effects of PARP-1 on ERK signaling are further enhanced by PARP-1-mediated transcription of vimentin, an intermediary angiogenic filament upregulated in tumor vasculature and pivotal for the endothelial-to-mesenchymal transition characteristic of metastasis (63). Pharmacologic inhibition of PARP reverted this transition, correlating with a reduction in the number and size of metastatic melanoma foci in a mouse model (63).

Collectively, these studies indicate PARP-1 directly fosters ERK signaling in addition to mediating separate but parallel signaling pathways reinforcing the same end result of increased angiogenesis and metastasis, two tumor-promoting features (Figure 1). As such, PARP inhibition may be effective in blocking the ERK signaling network or increasing activity of ERK/MEK inhibitors, agents already shown to be efficacious in acute myeloid leukemia, multiple myeloma, melanoma, colorectal, breast, lung, and pancreatic cancers (64–68). Furthermore, selective ERK inhibition induces tumor regression in MEK inhibitor-resistant models (67), raising the question of whether PARP inhibition could be similarly effective in either MEK or ERK-resistant tumors due to its proximity in the signaling pathway. As MEK, ERK, and PARP inhibitors have only recently entered early phase clinical trials, it will be some time before we know which patients benefit most from these drugs, either alone or in combination, but their interaction warrants further investigation.

MITOTIC REGULATION

The high proliferation rate of cancer cells is a result not only of decreased cell death but also of improperly regulated cell cycling, allowing evasion of growth suppressing signals. Although multiple cell cycle checkpoints can be impaired in cancer, the mitotic
or spindle assembly checkpoint is of great importance both in tumorigenesis and as an anticancer target. This point of regulation, which is responsible for ensuring appropriate chromosome segregation, is required for cell viability. Cells with a weakened mitotic checkpoint are capable of survival but do not maintain proper chromosome segregation, resulting in genomic instability and aneuploidy. These are common features of tumor cells and may even act as drivers in cancer development (Figure 1). PARP-1 can act on many mediators of cell cycle progression through its effects on gene expression (68), which will be detailed in a later section. However, direct regulation of the mitotic checkpoint by PARP-1 is another important factor that may be targetable in cancer treatment.

Recent reports suggest multiple roles for PARP-1 in the structural machinery of mitosis. First, PAR, which is primarily synthesized by PARP-1, is required for assembly and function of the bipolar spindle (69). In addition, PARP-1 both localizes to and PARylates proteins at centromeres and centrosomes during mitosis (70, 71). PARP-1 also mediates PARylation of p53, which is responsible for regulating centrosome duplication and monitoring chromosomal stability (71). Loss of PARP-activity is associated with mislocalization of centromeric and centrosomal proteins, resulting in incomplete synopsis of homologous chromosomes, defective chromatin modifications, and failure to maintain metaphase arrest, indicating loss of mitotic checkpoint integrity (71, 72). Similarly, inhibition of PARP-1 is associated with genomic instability characterized by reduced stringency of mitotic checkpoints, centrosome hyperamplification, and chromosomal aneuploidy, the most common characteristic of solid tumors (71, 73, 74).

Furthermore, PARP-1 has been shown to interact with the E3 ubiquitin ligase, CHFR, a tumor suppressor with an important role in the early mitotic checkpoint. Binding of these two proteins results in degradation of PARP-1 and cell cycle arrest in prophase, an effect stimulated by the microtubule inhibitor docetaxel resulting in resistance to this drug in CHFR-over-expressing cancer cells. Concomitant use of a PARP inhibitor with docetaxel significantly increased apoptosis in these cells, suggesting a role for PARP inhibition in sensitizing cancers with high CHFR activity to microtubule inhibitors (75).

**GENE TRANSCRIPTION**

The clinical characteristics of cancer, including growth, metastatic potential, and response to treatment, are greatly influenced by dysregulation of gene transcription. Gene expression profiles are currently being utilized as tumor biomarkers, indicators of treatment sensitivity or resistance, and prognostic predictors. In the future, there may even be a role for therapeutic agents that reactivate a silenced tumor suppressor or silence an activated oncogene. In total, 3.5% of the transcriptome is regulated by PARP-1 with 60–70% positively regulated (76), including genes involved in tumor promotion such as JUND, MDM2, HGF, FLT1 (VEGFR1), EGF, HIF2A (EPAS1), SPP1 (OPN), MMP28, ANGPT2, and PDGF (77). As discussed below and shown in Figure 4, this regulation can occur broadly through interactions with nucleosomes and modification of chromatin, can be gene specific through interactions with promoters and binding factors, or can result as a combination of the two, as binding of PARP-1 to nucleosomes mediates its localization to specific target gene promoters (78, 79).

**CHROMATIN STRUCTURE**

One mechanism by which PARP-1 alters gene expression is through regulation of chromatin structure and, thus, DNA accessibility. Simultaneous binding of multiple neighboring nucleosomes by PARP-1 compacts chromatin into a supranucleosomal structure, repressing gene transcription (79). This structural change is further stimulated by histone deacetylation mediated by a complex consisting of PARP-1, ATP-dependent helicase Brg1 (SmarcA4), and HDACs (80). Conversely, PARylation of core histones promotes charge repulsion-induced relaxation of chromatin and recruitment of transcription machinery (81–83). PARP-1-mediated PARylation also results in disassociation of linker histone H1, a repressor of RNA polymerase II-mediated transcription; accordingly, higher proportions of PARP-1:H1 indicate active promoters (84), suggesting potential utility of PARP-1 as a biomarker for actively transcribed genes. Although these outcomes can be separated by PARP-1 activity (protein binding versus enzymatic function), pharmacologic inhibition of PARP affect both actions, indicating manipulation of chromatin accessibility through PARP-1 is not currently an option for cancer therapy.

**METHYLATION PATTERNS**

Along with chromatin structure, methylation patterns also play a large role in determining DNA accessibility. Alterations in DNA methylation are commonly found in many cancers and serve as a functional equivalent to a gene mutation in the process of tumorigenesis. Inhibition of PARP-1 is associated with transcriptional silencing through accumulation of DNA methylation and CpG island hypermethylation throughout the genome (85). This effect may be mediated by dimerization of PARP-1 with CCCTC-binding factor (CTCF), a chromatin insulator which binds to hypomethylated DNA regions. As the CTCF-PARP-1 interaction is PAR-dependent, decreased PAR following PARP inhibition abrogates this function (86, 87). Loss of CTCF-PARP-1 complex activity results in transcriptional silencing of multiple loci including tumor suppressors CDKN2A-INK4 (p16), CDH1 (e-cadherin), and P19ARF (88, 89).

Poly(ADP-ribose) polymerase-1 can also hinder DNA methylation by dimerization with DNA (cytosine-5-) -methyltransferase 1 (DNMT1), a methyltransferase found overexpressed in gastrointestinal tract carcinomas, resulting in inhibition of its methyltransferase activity (85, 90). In contrast, PARP-1 binding and PARylation of the Dnmt1 promoter actually enhances its transcription by preventing methylation-induced silencing (91). The reduced catalytic efficiency of PARylated DNMT1 may come as a result of negatively charged PARylated PARP-1 out-competing DNA for binding with DNMT1 (92). Interestingly, PARP-1-DNMT1 can form a ternary complex with CTCF at unmethylated CTCF-target sites in a PAR-dependent manner. Loss of PAR from this complex causes dissociation of PARP-1 and CTCF, allowing the still-bound DNMT1 to methylate the site and inhibit transcription (92).

Although some specific tumor suppressors are mentioned above as being affected by PARP-1-mediated chromatin insulation, the activity of PARP-1 in regulating DNA methylation patterns
Figure 4 | Poly(ADP-ribose) polymerase-1 regulates gene transcription through multiple mechanisms. (1) PARP-1 binds neighboring nucleosomes resulting in chromatin compaction. (2) PARP-1 PARylation of core histones mediates chromatin relaxation. (3) PARP-1 promotes hypomethylation of DNA by enhancing the chromatin insulator activity of CCCTC-binding factor (CTCF) while inhibiting methyltransferase activity of DNMT1. (4) PARP-1 promotes loading and retention of RNA polymerase II at active promoters. (5) PARP-1 binds regulatory DNA sequences and transcription factors, PARylates transcription factors, and recruits additional regulatory binding proteins in a target gene specific manner.

at specific genes or genomic regions is largely unknown. As such, it is difficult to predict the effect of PARP inhibition on cancer growth and progression through this mechanism. However, with the advent of genomic profiling, it has recently become possible to identify methylation changes specific to certain cancer subtypes. Anticancer agents with epigenetic modifying activity, such as DNA methyltransferase inhibitors, are being investigated in these cancers and show promising results, especially in hematologic malignancies (93). The effect of PARP inhibition on epimutations has not been studied, but the reports described above suggest PARP inhibitors could have similar applicability.

RNA POLYMERASE II ACTIVITY
Poly(ADP-ribose) polymerase-1 can also promote transcription in a more sequence-specific manner by positively regulating RNA polymerase II activity at active promoters. This occurs through: (1) PARylation-induced exclusion of histone demethylase KDM5B, maintaining levels of activating histone mark K3K4me3 (82), (2) PARylation-induced dissociation of the DEK repressor, promoting loading of the RNA polymerase II mediator complex (94), and (3) creation of a PAR scaffold for retention of RNA polymerase II (95). Surprisingly, a recent report showed that inhibition of PARP-1 enzymatic activity was associated with increased H3K4me3, resulting in upregulation of sodium iodide symporter transcription and elevated radioiodine uptake in thyroid cancer cell lines (96). This contradictory work may result from target gene specific functions of PARP-1, as the previously cited studies were focused on genes known to be positively regulated by PARP-1. However, it does illustrate the need for greater understanding of PARP-1 involvement at active gene promoters, as well as the potential for manipulating PARP-1-mediated transcription to enhance efficacy of cancer therapy.

DNA AND TRANSCRIPTION FACTOR BINDING
Gene expression can be further regulated by direct interactions between PARP-1 and DNA elements or binding factors. PARP-1 acts as a promoter-specific switch at target genes, facilitating the release of inhibitory co-regulators and recruitment of stimulatory co-regulators (97, 98). PARP-1 binding of the NF-κB immediate upstream region (IUR) element activates transcription of CXCL1, which encodes melanoma growth stimulatory activity protein and is overexpressed in the progression of malignant melanoma (99). Binding of PARP-1 to the transcription factor E2F-1 increases E2F-1 promoter activity and expression of the E2F-1-responsive oncogene Myc (c-Myc) (100). PARP-1 expression and activity are also required for cancer cell invasion (Figure 1) mediated by ETS transcription factors – whose fusion products drive Ewing’s sarcoma, acute myeloid leukemia, and prostate cancer – and the Ewing’s sarcoma fusion protein EWS-FLI (14, 15). While PARP-1 interaction with these factors promotes pro-tumor signaling, other interactions have the opposite effect. PARP-1 suppresses self-inhibition of AP-2, a transcription factor that negatively regulates
Table 1 | Summary of reported non-DNA repair functions of PARP-1 with potential clinical correlations.

| PARP-1 function | Effect | Model system studied | Clinical applicability of PARP inhibition |
|-----------------|--------|----------------------|------------------------------------------|
| Binding histone acetyl-transferases p300/CBP | Co-activation of NFκB (pro-inflammatory) | In vitro and in vivo HER2+ breast cancer cell lines | May inhibit cancer metastasis; cytotoxicity in HER2-positive breast cancer specifically (13, 21, 22) |
| Binding DNMT1 | Enhances Dnmt1 transcription, inhibits methyltransferase activity | In vitro mouse fibroblasts | May have activity in DNMT1-overexpressing colorectal, gastric, and hepatic carcinomas (85, 91, 92) |
| Binding pERK2 | Promotes target gene transcription | In vitro endothelial cells | May inhibit cancer growth and metastasis (58) |
| Binding CHFR | Prophase arrest, resistance to microtubule inhibitors | In vitro gastric carcinoma cell lines | Re-sensitizes CHFR-expressing cancers to microtubule inhibitor therapy (75) |
| Downregulation of MKP-1 and inhibition of Akt | Activation of JNK | In vitro hepatocytes | May have activity in tumors with high JNK activity (46, 47) |
| AutoPARylation | Activation of NFκB (pro-inflammatory) | In vitro and in vivo HER2+ breast cancer cell lines | May inhibit cancer metastasis; cytotoxicity in HER2-positive breast cancer specifically (13) |
| Caspase-8 PARylation | Impaired apoptotic signaling | In vitro and in vivo pancreatic cancer cell lines | Sensitizes cancer cells to TRAIL therapy (37) |
| PARylation | ATP depletion, promotes necrosis and autophagy | Mouse and rat kidney and heart studies | Prevents cell death mediated toxicities of multiple chemotherapy agents (42, 43, 52) |
| PARylation of transcription regulators | Promotes transcription | In vitro thyroid cancer cell lines | Upregulates Nal symporter transcription leading to increased radio-iodine uptake in thyroid cancer (98) |
| Androgen receptor PARylation | Increases androgen receptor activity | In vivo and ex vivo prostate cancer cells | Sensitizes prostate cancer to androgen depletion, enhances effects of anti-androgen therapy, delays onset of resistance to anti-androgen therapy (110) |
| ETS and EWS-FLI PARylation | Promotes transcription of target genes | In vivo and in vitro prostate cancer and sarcoma cells | Cytotoxicity in ETS-prostate cancer and EWS-FLI Ewing’s sarcoma specifically (14, 15) |
| Vimentin promoter PARylation | Promotes transcription | In vitro melanoma cells and in vivo melanoma model | Inhibits cancer metastasis (63) |
| Interaction with VEGF SDC-4, PECAM1/CD31, HIF promoters | Promotes transcription | In vitro endothelial cells | Inhibits tumor angiogenesis (58–62) |

cell cycle and proliferation (101). Increased AP-2 expression suppresses cancer cell growth (102) and may inhibit ras oncogene-mediated transformation (101), effects likely diminished by PARP inhibition (Figure 1). PARP-1 has also been shown to bind the inhibitory element of COX-2, which mediates inflammation and promotes VEGF-mediated pro-angiogenesis pathways activated in cancer cells (103, 104).

Instances of PARP-1-mediated enzymatic activity affecting specific transcription factors or genes often translate to a clear role for PARP-1 inhibitors as anticancer agents, even in monotherapy. For example, ETS-positive prostate tumors and EWS-FLI-positive Ewing’s sarcomas are highly sensitive to PARP inhibitors (14, 15). However, PARP-1 has multiple and diverse functions involving both PARylation activity and DNA-binding capability. Enzymatic inhibition, which decreases PARP-1 self PARylation, actually increases DNA binding and may be detrimental in some cancers, such as the malignant melanoma example given above. A greater understanding of the relative effects of PARP-1 on transcriptional activity is needed in order to select tumors with a molecular profile conducive to pharmacologic inhibition through this mechanism.

**SEX HORMONE SIGNALING**

Sex hormones have been implicated in development, progression, and treatment sensitivity of prostate, breast, gynecologic, and colon cancers. Sex steroid effects are mediated through their receptors, which act as transcription factors in steroid-responsive tissues. Any of the multiple levels of regulation controlling these signaling pathways can become impaired, leading to abnormal proliferative responses characteristic of cancer progression (Figure 1). Similar to PARP-1-mediated regulation of transcription factor activity, PARP-1 plays a role in regulating three of the sex hormone receptors most commonly linked to cancer: estrogen receptor (ER), progesterone receptor (PR), and androgen receptor (AR).

Approximately 80% of breast carcinomas are positive for ER, identifying ER-targeted therapies as excellent, although not unfailable, treatment options in these cancers (105). PARP-1 interacts...
with the ERα isoforms both directly and through estradiol-induced PARylation to enhance binding of ERα and other activating factors to target gene promoters (106, 107), suggesting PARP inhibition may enhance the activity of ER-targeted agents. A similar interaction occurs between PARP-1 and PR: PARP-1 binding of PR, as well as hormone-activated CDK2-induced PR PARylation, acts to stimulate cancer cell proliferation (108). PARP-1 regulation of PR activity is of great interest in endometrial carcinomas specifically, as expression of PARP-1 and PR is positively correlated at each pathologic stage of this cancer (109). However, the effects of PARP inhibition in endometrial cancer have yet to be determined.

Recently, a report detailing the strong interaction between PARP-1 and AR has generated much excitement over the potential for PARP inhibitors in prostate cancer treatment. Human prostate adenocarcinoma, a cancer highly resistant to standard therapies, is reliant on AR activity for growth and survival. Accordingly, AR-targeted therapies are the primary treatment for these patients. Unfortunately, there are multiple mechanisms for AR reactivation leading to tumor recurrence, a lethal phenotype known as castration-resistant prostate cancer. PARP-1 enzymatic activity, which is significantly upregulated in castration-resistant prostate cancer, promotes both AR chromatin binding and transcription factor functions. Although PARP-1 does localize with AR to regulatory sites of AR-target genes, the two proteins appear to be members of separate complexes at these loci. Inhibition of PARP-1 in vivo (1) depletes both PARP-1 and AR at target genes, (2) significantly reduces expression of target genes, including pro-tumorigenic ets genes referenced previously, (3) sensitizes both castration-resistant and castration-sensitive prostate cancer cells to genotoxic insult and androgen depletion, (4) enhances the anti-tumor effects of anti-androgen therapy, and (5) delays onset of resistance to anti-androgen therapy. Ex vivo studies of castration resistance prostate tumors displayed a significant anti-tumor response to both veliparib and olaparib, two well-known PARP inhibitors, that correlates with reduced AR activity (110). These results suggest PARP inhibitors have the potential to significantly enhance existing prostate cancer therapy and improve outcomes for patients with castration-resistant tumors.

**REFERENCES**

1. Houtgraaf JH, Versmissen J, van der Giessen WJ. A concise review of DNA damage checkpoints and repair in mammalian cells. *Cardiovasc Res* (2006) 73(3):165–72. doi:10.1016/j.cardiores.2006.02.002
2. Calabrese CR, Almassy R, Barton S, Baty MA, Calvert AH, Canan-Koch S, et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. *J Natl Cancer Inst* (2004) 96(1):56–67. doi:10.1093/jnci/djh005
3. Plummer R, Jones C, Middleton M, Wilson R, Evans J, Olsen A, et al. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumours. *Clin Cancer Res* (2008) 14(23):7917–23. doi:10.1158/1078-0432.CCR-08-1223
4. Khan OA, Gore M, Lorigan P, Stone J, Greystoke A, Burke W, et al. A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. *Br J Cancer* (2011) 104(5):750–5. doi:10.1038/bjc.2011.8
5. Kimmar S, Ji J, Morgan R, Lenz HJ, Puhalla SL, Belani CP, et al. A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. *Clin Cancer Res* (2012) 18(6):1726–34. doi:10.1158/1078-0432.CCR-11-2821
6. Noweens S, Bonner JA, Yang ES. The poly(ADP-ribose) polymerase inhibitor ABT-888 reduces radiation-induced nuclear EGFR and augments head and neck radiation response. *Clin Cancer Res* (2012) 18(20):5481–90. doi:10.1158/1078-0432.CCR-12-1333

**AUTHOR CONTRIBUTIONS**

Alice N. Weaver and Eddy S. Yang conceptualized the topic. Alice N. Weaver conducted the literature review and wrote the article. Eddy S. Yang critically reviewed the article and provided guidance and supervision.

**ACKNOWLEDGMENTS**

We apologize to colleagues whose work was not cited due to space constraints. We would like to thank Amanda Swindall, Jennifer Stanley, Monica Wielgos, and Tiffany Cooper for assistance in preparing the manuscript. This work is supported by grants from the Department of Defense (Eddy S. Yang), the American Association of Cancer Research (Eddy S. Yang), and the ST32GM008361-21 grant from the NIH-National Institute of General Medical Sciences (Alice N. Weaver).
Weaver and Yang

Non-DNA repair functions of PARP-1

25. Chang WJ, Alvarez-Gonzalez R. The sequence-specific DNA binding of NF-
22. Hassa PO, Haenni SS, Buerki C, Meier NI, Lane WS, Owen H, et al. Acetylation
11. Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K,
15. Brenner JC, Feng FY, Han S, Patel S, Goyal SV, Bou-Maroun LM, et al. PARP-1
6. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific
8. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. PARP-1
12. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific
14. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. PARP-1
7. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific
17. Addioui A, Belounis A, Cournoyer S, Nyalendo C, Brito R-M, Beaunoyer M,
10. Naura AS, Datta R, Hans CB, Zerfaoui M, Rekz BM, Eramsi Y, et al. Reciprocal
9. Racz I, Tori K, Gallyas F Jr, Berente Z, Osz E, Jaszlits L, et al. BGP-15 – a novel
42. Racz I, Tori K, Gallyas F Jr, Berente Z, Osz E, Jaszlits L, et al. BGP-15 – a novel
43. Schedel C, Meier NI, Lane WS, Owen H, et al. Acetylation of poly(ADP-ribose)
45. Yang Y, Ikezoe T, Saito T, Kobayashi M, Koeffler HP, Taguchi H. Proteasome
46. Wesierska-Gadek J, Ranftler C, Schmid G. Physiological ageing: role of p53 and PARP-1 in ETS gene fusion-accelerated lung cancer cells via the JNK/c-Jun/AP-1 signaling.
41. Racz I, Tori K, Gallyas F Jr, Berente Z, Osz E, Jaszlits L, et al. BGP-15 – a novel poly(ADP-ribose) polymerase inhibitor that induces growth arrest and apoptosis in non-small cell lung cancer.
40. Racz I, Tori K, Gallyas F Jr, Berente Z, Osz E, Jaszlits L, et al. BGP-15 – a novel poly(ADP-ribose) polymerase inhibitor that induces growth arrest and apoptosis in non-small cell lung cancer.
39. Soldani C, Scovassi AI. Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update. Apoptosis (2007) 12(4):397–409.
38. Wesierska-Gadek J, Ranftler C, Schmid G. Physiological ageing: role of p53 and PARP-1 in terminal senescence.
Weaver and Yang
Non-DNA repair functions of PARP-1

52. Sarszegi Z, Bognar E, Gaszner B, Konyi A, Gallyas F Jr, Sumegi B, et al. BGP-15, a PARP-1 inhibitor, induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. Blood (2010) 115(1):1565–63. doi:10.1182/blood-2007-03-181240

53. Boucher MJ, Morisset J, Vachon PH, Reed JC, Laine J, Rivard N. MEK/ERK activation inhibits the metastatic potential of melanoma cells via reduction in response to a DNA alkylating agent. Mol Aspects Med (2003) 24(1-2):129–37. doi:10.1016/S0093-2760(03)00010-2

54. Sarszegi Z, Bognar E, Gaszner B, Konyi A, Gallyas F Jr, Sumegi B, et al. BGP-15, a PARP-1 inhibitor, prevents imatinib-induced cardiotoxicity by activating Akt and suppressing JNK and p38 MAP kinases. J Pharmacol Exp Ther (2013) 341(1):24–32. doi:10.1124/jpet.112.188706

55. Kim HS, Kim MJ, Kim EJ, Yang Y, Lee MS, Lim JS. Berberine-induced AMPK activation by phosphorylated ERK2 increases Akt phosphorylation in response to a DNA alkylating agent. Mol Cell Biochem (2012) 365(1-2):129–37. doi:10.1007/s11010-012-1252-8

56. Kohno M, Tanimura S, Ozaki K. Targeting the extracellular signal-regulated kinase mediates hydrogen peroxide-induced cell death via sustained poly(ADP-ribose)polymerase-1 activation. Cell Death Differ (2007) 14(5):1001–10. doi:10.1038/sj.cdd.4402088

57. Virag L, Robaszkiwicz A, Vargas JM, Javier Oliver F. Poly(ADP-ribose) polymerase inhibition in cell death. Mol Aspects Med (2013) 34(6):1153–67. doi:10.1016/j.mam.2013.01.007

58. Pyriochou A, Olah G, Deitch EA, Szabo C, Papapetropoulos A. Inhibition of DNA-dependent PARP-1 activation by phosphorylated ERK2 increases Akt phosphorylation in response to a DNA alkylating agent. Mol Aspects Med (2012) 33(3):385–94. doi:10.1016/j.mam.2011.11.008

59. Kohno M, Tanimura S, Otaki K. Targeting the extracellular signal-regulated kinase pathway in cancer therapy. Biol Pharm Bull (2011) 34(12):1781–4. doi:10.1248/bpb.43.1781

60. Cohen-Armon M, Viscochek L, Rozenas D, Kalal A, Geistrik I, Klein R, et al. DNA-dependent PARP-1 activation by phosphorylated ERK2 increases ERK1 activity: a link to histone acetylation. Mol Cell (2007) 25(2):297–308. doi:10.1016/j.molcel.2006.12.012

61. Pyriochou A, Olah G, Deitch EA, Szabo C, Papapetropoulos A. Inhibition of angiogenesis by the poly(ADP-ribose) polymerase inhibitor PJ-34. Int J Mol Med (2008) 22(1):113–8.

62. Lacal PM, Tentori L, Muzi A, Ruffini F, Dorio AS, Xu W, et al. Pharmacological inhibition of poly(ADP-ribose) polymerase activity down-regulates the expression of syndecan-4 and Id-1 in endothelial cells. Int J Oncol (2003) 23(4):861–72. doi:10.3892/ijo_00000213

63. Tentori L, Muzi A, Dorio AS, Bultrini S, Mazzeno E, Lacal PM, et al. Stable depletion of poly (ADP-ribose) polymerase-1 reduces in vivo melanoma growth and increases chemosensitivity. Eur J Cancer (2008) 44(9):1302–14. doi:10.1016/j.ejca.2008.03.019

64. Martin-Oba D, Aguilar-Quesada R, O’Valle F, Munoz-Gamez JA, Martinez-Romo R, Garcia Del Moral R, et al. Inhibition of poly(ADP-ribose) polymerase modulates tumor-related gene expression, including hypoxia-inducible factor-1 activity, during skin carcinogenesis. Cancer Res (2006) 66(11):5744–56. doi:10.1158/0008-5472.CAN-05-3050

65. Rajesh M, Mukhopadhyay P, Godlewski G, Baitai S, Hasko G, Liuzzi L, et al. Poly(ADP-ribose)polymerase inhibition decreases angiogenesis. Biochem Biophys Res Commun (2006) 350(4):1056–62. doi:10.1016/j.bbrc.2006.09.160

66. Rodriguez MI, Peralta-Leal A, O’Valle F, Rodriguez-Vargas JM, Gonzalez-Flores A, Majuelos-Melguizo J, et al. PARP-1 regulates metastatic melanoma through modulation of vimentin-induced malignant transformation. PLoS Genet (2013) 9(6):e1003531. doi:10.1371/journal.pgen.1003531

67. Yeh TC, Marsh V, Bernat BA, Ballard J, Cobwell H, Evans RJ, et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res (2007) 13(5):1576–83. doi:10.1158/1078-0432.CCR-06-1150

68. Lee P, Wallace E, Yeh T, Poch G, Litwiler K, Pheneger T et al. ARRY-142886, a potent and selective MEK inhibitor: III efficacy in murine xenograft models correlates with decreased ERK phosphorylation. Proc Am Assoc Cancer Res (2004) 45:3890.

69. Zhang F, Jacobson MK, Mitchison TJ. Poly(ADP-ribose) is required for spindle assembly and structure. Nature (2004) 432(7017):645–9. doi:10.1038/nature03061

70. Wang S, Wang H, Davis BC, Liang J, Cui R, Chen SJ, et al. PARP1 inhibitors attenuate Akt phosphorylation via the upregulation of FHBP1P1. Biochem Biophys Res Commun (2011) 412(2):379–84. doi:10.1016/j.bbrc.2011.07.077

71. Sansepolcro I, Bognar E, Gaszner B, Konyi A, Gallyas F Jr, Sumegi B, et al. BGP-15, a PARP-1 inhibitor, prevents imatinib-induced cardiotoxicity by activating Akt and suppressing INK and p38 MAP kinases. Mol Cell Biochem (2012) 365(1-2):129–37. doi:10.1007/s11010-012-1252-8

72. Kanai M, Tong WM, Sugihara E, Wang ZQ, Fukasawa K, Miwa M. Involvement of poly(ADP-ribose) polymerase 1 and poly(ADP-ribose)polymerase inhibition in regulation of centrosome function. Mol Cell Biochem (2003) 237(1-2):2451–62. doi:10.1016/S0300-9021(03)00751-1

73. Varghese R, Sheehan P, Essen RC, Lui X, Arora S, Madbouly H, et al. PARP-1 regulates metastatic melanoma cell growth and increases chemosensitivity. Proc Natl Acad Sci U S A (2011) 108(1):2805–10. doi:10.1073/pnas.1016441108

74. Kerr AHJ, James MA, Willson C, Court EL, Smith JG. An investigation of tumor-related gene expression. Proc Natl Acad Sci U S A (2001) 98(23):12451–6. doi:10.1073/pnas.161240

75. Halappanavar SS, Shah GM. Defective control of mitotic and post-mitotic checkpoints in poly(ADP-ribose) polymerase (Parp-1) null oocytes. Dev Biol (2009) 321(2):326–38. doi:10.1016/j.ydbio.2008.05.050

76. Ogino H, Nozaki T, Gunji A, Maeda M, Suzuki H, Ohta T, et al. Loss of Parp-1 increases peroxisome proliferator-activated receptor gamma coactivator 1alpha (PGC-1alpha) expression and promotes survival of human pancreatic cancer cells. J Cell Biochem (2012) 112(8):1348–57. doi:10.1002/jcb.24129

77. Chang P, Jacobson MK, Mitchison TJ. Poly(ADP-ribose) is required for spindle assembly and structure. Nature (2004) 432(7017):645–9. doi:10.1038/nature03061
83. Kraus WL, Lis JT. PARP goes transcription. Cell (2003) 113(6):877–83. doi:10.1016/S0092-8674(03)00433-1
84. Fruzzetti KM, Gamble MJ, Berrocal YG, Zhang T, Krishnakumar R, Cem Y, et al. Global analysis of transcriptional regulation by poly(ADP-ribose) polymerase-1 and poly(ADP-ribose) glycohydrolase in MCF-7 human breast cancer cells. J Biol Chem (2009) 284(49):39326–38. doi:10.1074/jbc.M109.023879
85. Reale A, Mattei GD, Galleazzi G, Zampieri M, Caiafa P. Modulation of DNMT1 activity by PARP-ribomere polymers. Oncogene (2005) 24(1):13–9. doi:10.1038/sj.onc.1208005
86. Yu W, Ginjala V, Pann V, Cherukhin I, Whitehead JD, Desterke F, et al. Poly(ADP-ribose)ylation regulates CTCF-dependent chromatin insulation. Nat Genet (2004) 36(10):1105–10. doi:10.1038/ng1426
87. Ong CT, Van Bortle K, Ramos E, Corces VG. Poly(ADP-ribosyl)ation regulates insulator function and intrachromosomal interactions in Drosophila. Cell (2013) 155(1):148–59. doi:10.1016/j.cell.2013.08.052
88. Witmer M, Emerson BM. Epigenetic silencing of the p16(INK4a) tumor suppressor is associated with loss of CTCF binding and a chromatin boundary. Mol Cell (2009) 34(3):271–84. doi:10.1016/j.molcel.2009.04.001
89. Farrar D, Rai S, Cherukhin I, Ito Y, Yammine S, et al. Muta-1 and poly(ADP-ribose) polymerase 1 is a key regulator of estrogen receptor alpha-dependent gene transcription. J Biol Chem (2009) 284(26):17026–36. doi:10.1074/jbc.M108.683210
90. Zampieri M, Calabrese R, Ciccarone F, Bacalini MG, Reale A, et al. Poly(ADP-ribose) polymerase 1 binds E2F-1 independently of its DNA binding and catalytic domains, and acts as a novel coactivator of E2F-1-mediated transcription during re-entry of quiescent cells into S phase. Oncogene (2003) 22(52):8460–71. doi:10.1038/sj.onc.1206897
91. Kanan P, Yu Y, Wankhade S, Tainsky MA. Poly(ADP-ribose) polymerase is a coactivator for AP-2-mediated transcriptional activation. Nucleic Acids Res (1999) 27(3):866–74. doi:10.1093/nar.27.3.866
92. Zobeck KL, Buckley MS, Zipfel WR, Lis JT. Recruitment timing and dynam-ulation of mediator. Mol Cell (2005) 18(4):393–96. doi:10.1016/j.molcel.2005.02.034
93. Nirodi C, NagDas S, Gygi SP, Olson G, Aebischer R, Richmond A. A role for poly(ADP-ribose) polymerase in the transcriptional regulation of the melanoma growth stimulatory activity (CXCL1) gene expression. J Biol Chem (2001) 276(12):9366–74. doi:10.1074/jbc.M109897200
94. Simbulan-Rosenthal CM, Rosenthal DS, Luo R, Samara R, Espinosa LA, Hassa PO, et al. PARP-1 binds E2F-1 independently of its DNA binding and catalytic domains, and acts as a novel coactivator of E2F-1-mediated transcription during re-entry of quiescent cells into S phase. Oncogene (2003) 22(52):8460–71. doi:10.1038/sj.onc.1206897
95. Gamble MJ, Fisher RP. SET and PARP1 remove DEK from chromatin to permit access by the transcription machinery. Nat Struct Mol Biol (2010) 17(5):548–55. doi:10.1038/nsmb.1248
96. Zobeck KL, Buckley MS, Zipfel WR, Lis JT. Recruitment timing and dynam-ics of transcription factors at the Hsp70 loci in living cells. Mol Cell (2010) 40(6):965–75. doi:10.1016/j.molcel.2010.11.022
97. Lavarone E, Puppin C, Passon N, Filetti S, Russo D, Damante G. The roles of PARP-1 in endometrial cancer and its precursors. Int J Cancer (2004) 113(1):112–9. doi:10.1002/ijc.120193.112
98. Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA, et al. Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov (2012) 2(12):1134–49. doi:10.1158/2155-9259.CD-12-0120
99. Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature (2008) 451(7182):1111–5. doi:10.1038/nature06548

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 20 September 2013; accepted: 13 November 2013; published online: 27 November 2013.

Citation: Weaver AN and Yang ES (2013) Beyond DNA repair: additional functions of PARP-1 in cancer. Front. Oncol. 3:290. doi: 10.3389/fonc.2013.00290
This article was submitted to Cancer Molecular Targets and Therapeutics, a section of the journal Frontiers in Oncology.

Copyright © 2013 Weaver and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.